WCN24-748 ASSESSMENT OF THE EFFECT OF HEPATIC IMPAIRMENT ON IPTACOPAN PHARMACOKINETICS

WCN24-748 ASSESSMENT OF THE EFFECT OF HEPATIC IMPAIRMENT ON IPTACOPAN PHARMACOKINETICS

Saved in:

Bibliographic Details
Main Authors:	Robert Schmouder, Kenneth Kulmatycki, Elise Burmeister Getz, Wendy Weiss, Bharti Shah
Format:	Article
Language:	English
Published:	Elsevier 2024-04-01
Series:	Kidney International Reports
Online Access:	http://www.sciencedirect.com/science/article/pii/S246802492400319X
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

WCN24-555 PHARMACOKINETICS OF SINGLE DOSES OF IPTACOPAN
by: Robert Schmouder, et al.
Published: (2024-04-01)

WCN24-750 ASSESSMENT OF DRUG INTERACTIONS WITH IPTACOPAN
by: Robert Schmouder, et al.
Published: (2024-04-01)

WCN24-550 SINGLE DOSE OF IPTACOPAN TREATMENT RAPIDLY DESCREASES PLASMA COMPLEMENT Bb LEVELS
by: Robert Schmouder, et al.
Published: (2024-04-01)

WCN25-797 SAFETY AND EFFICACY OF IPTACOPAN IN PATIENTS WITH IgA NEPHROPATHY (IgAN) WITH BASELINE eGFR 20-<30 mL/MIN: PHASE 3 APPLAUSE-IgAN SUBCOHORT RESULTS
by: Dmitrij Kollins, et al.
Published: (2025-02-01)

P748: The role of PACS2 and pacs2 in ocular development
by: Courtney Linne, et al.
Published: (2025-01-01)

WCN24-1146 SAFETY AND EFFICACY OF IPTACOPAN IN ADOLESCENT PATIENTS WITH IDIOPATHIC (PRIMARY) IMMUNE-COMPLEX-MEDIATED MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS (IC-MPGN)
by: Nicholas Webb, et al.
Published: (2024-04-01)

WCN24-1506 EFFICACY AND SAFETY OF IPTACOPAN IN PATIENTS WITH IgA NEPHROPATHY: INTERIM RESULTS FROM THE PHASE 3 APPLAUSE-IgAN STUDY
by: Vlado Perkovic, et al.
Published: (2024-04-01)

Productivity loss due to menstruation-related symptoms: a nationwide cross-sectional survey among 32 748 women
by: Mark E Schoep, et al.
Published: (2019-06-01)

Effect of Hepatic Impairment on the Pharmacokinetics of Baicalin in Rats: Critical Roles of Gut Microbiota and Hepatic Transporters
by: Ping Li, et al.
Published: (2025-06-01)

Iptacopan Reduces Proteinuria and Stabilizes Kidney Function in C3 Glomerulopathy
by: Carla M. Nester, et al.
Published: (2025-02-01)

WCN25-799 EFFICACY AND SAFETY OF IPTACOPAN IN PATIENTS WITH IgA NEPHROPATHY (IgAN): INTERIM ANALYSIS (IA) OF THE PHASE 3 APPLAUSE-IgAN STUDY
by: Dmitrij Kollins, et al.
Published: (2025-02-01)

WCN25-716 EFFECT OF IPTACOPAN ON PROTEINURIA AND COMPLEMENT BIOMARKERS IN IgA NEPHROPATHY (IgAN): INTERIM ANALYSIS OF THE PHASE 3 APPLAUSE-IgAN STUDY
by: Dmitrij Kollins, et al.
Published: (2025-02-01)

Efficacy of iptacopan monotherapy for suboptimal response to eculizumab in patients with paroxysmal nocturnal hemoglobinuria
by: Olesya U. Klimova, et al.
Published: (2025-01-01)

The treatment of autoimmune hemolytic anemia with complement inhibitor iptacopan: a case report
by: Xiaoqing Li, et al.
Published: (2025-03-01)

WCN24-320 ISCHEMIC HEPATITIS IN CARDIO RENAL SYNDROME: CASE REPORT
by: MAIKOALEJANDROTAVERA DIAZ, et al.
Published: (2024-04-01)

Assessment of pharmacokinetics and tolerability following single‐dose administration of molnupiravir in participants with hepatic or renal impairment
by: Kelly E. Duncan, et al.
Published: (2024-12-01)

Case Report: Iptacopan in a paroxysmal nocturnal hemoglobinuria patient with severe renal insufficiency
by: Ting Wu, et al.
Published: (2025-08-01)

WCN25-2041 EFFICACY AND SAFETY OF IPTACOPAN IN PATIENTS WITH C3 GLOMERULOPATHY: 12-MONTH RESULTS FROM THE PHASE 3 APPEAR-C3G STUDY
by: Carla Nester, et al.
Published: (2025-02-01)

Physiologically based pharmacokinetic modeling to predict the effect of risperidone on aripiprazole pharmacokinetics in subjects with different CYP2D6 genotypes and individuals with hepatic impairment
by: Fan Mou, et al.
Published: (2024-12-01)

Pharmacokinetics of Bocidelpar, ASP0367, in Renal and Hepatic Impairment: Results From Two Phase 1 Studies
by: Megumi Iwai, et al.
Published: (2025-08-01)

Successful treatment of transplant-associated thrombotic microangiopathy with iptacopan: a non-adult case study
by: Shijie Bao, et al.
Published: (2025-08-01)

WCN24-5 Feasibility study evaluating neurological impairment in critically ill dialysis patients
by: Natasha Jawa, et al.
Published: (2024-04-01)

WCN24-2273 COGNITIVE IMPAIRMENT IN DIALYSIS PATIENTS IN NORTHEN GAUTENG PROVINCE, SOUTH AFRICA
by: A.L.B.E.R.T.Z. MURANDA, et al.
Published: (2024-04-01)

Advances in Canine Anesthesia: Physiologically Based Pharmacokinetic Modeling for Predicting Propofol Plasma Profiles in Canines with Hepatic Impairment
by: Lucas Wamser Fonseca Gonzaga, et al.
Published: (2024-12-01)

WCN24-2197 INTRADERMAL HEPATITIS B VACCINATION IN PATIENTS WITH CHRONIC KIDNEY DISEASE IN DIALYSIS
by: Daniela Wojtowicz, et al.
Published: (2024-04-01)

WCN24-861 SUBCLINICAL RHABDOMYOLYSIS IN MESOAMERICAN NEPHROPATHY
by: Magdalena Madero, et al.
Published: (2024-04-01)

Successful targeting of the alternative complement cascade with iptacopan for the treatment of IgA nephropathy: a case report
by: Leonore Ingold, et al.
Published: (2025-06-01)

Patient-reported improvements in paroxysmal nocturnal hemoglobinuria treated with iptacopan from 2 phase 3 studies
by: Antonio M. Risitano, et al.
Published: (2025-04-01)

Effectiveness of Iptacopan Versus C5 Inhibitors in Complement Inhibitor‐Naive Patients With Paroxysmal Nocturnal Haemoglobinuria
by: Matthew Holt, et al.
Published: (2025-06-01)

WCN24-2325 EXECUTIVE IMPAIRMENT IN PATIENTS WITH CHRONIC KIDNEY DISEASE ON REPLACEMENT THERAPY: PRELIMINARY DATA
by: gaston alvarez, et al.
Published: (2024-04-01)

WCN25-1242 UPDATE TO THE LONG-TERM SAFETY AND EFFICACY OF IPTACOPAN IN C3G: 33-MONTH EXTENSION STUDY DATA FROM PATIENTS ENROLLED IN A PHASE 2 STUDY
by: Carla Nester, et al.
Published: (2025-02-01)

Tailoring oral targeted therapies dosage in lung cancer: A systematic review of pharmacokinetics studies on renal and hepatic impairment
by: Harri Hardi, et al.
Published: (2025-01-01)

Tailoring oral targeted therapies dosage in lung cancer: A systematic review of pharmacokinetics studies on renal and hepatic impairment.
by: Harri Hardi, et al.
Published: (2025-01-01)

Iptacopan in Idiopathic Immune Complex–Mediated Membranoproliferative Glomerulonephritis: Protocol of the APPARENT Multicenter, Randomized Phase 3 Study
by: Marina Vivarelli, et al.
Published: (2024-01-01)

WCN24-2609 ADOLESCENT NEPHRONOPTHISIS CAUSED BY AN NPHP 1 GENE MUTATION
by: Yesha Shah, et al.
Published: (2024-04-01)

WCN24-177 GLOMERULOPATIA COLAPSANTE
by: vanessa emilia oreyano zamora, et al.
Published: (2024-04-01)

WCN24-1155 CORRELATION OF KLOTHO PROTEIN, BIOMARKERS OF ENDOTHELIAL DAMAGE AND COGNITIVE IMPAIRMENT IN PATIENTS WITH CHRONIC KIDNEY DISEASE
by: Anaiara Lucena Queiroz, et al.
Published: (2024-04-01)

Evaluating the Impact of Hepatic or Renal Impairment on Tanimilast (CHF6001) Pharmacokinetics: Two Open‐Label, Parallel‐Group, Single‐Center Studies
by: Annalisa Piccinno, et al.
Published: (2025-05-01)

Synthesis, Characterization, and Pharmacokinetic Studies of Thiazolidine-2,4-Dione Derivatives
by: Bushra Ansari, et al.
Published: (2023-01-01)

Prediction of drug exposure in hepatic impairment: a comparison between minimal physiologically based pharmacokinetic (mPBPK) and whole body PBPK models
by: Iftekhar Mahmood
Published: (2025-02-01)